Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Sorafenib 37Nivolumab 21pembrolizumab 18Bevacizumab 12Cyclophosphamide 10durvalumab 9fludarabine 8atezolizumab 8Magnetic Resonance Spectroscopy 8lenvatinib 7Radiosurgery 7Ipilimumab 7Radiotherapy 6Irinotecan 6Oxaliplatin 5Leucovorin 5tremelimumab 4toripalimab 4tislelizumab 4sintilimab 4cabozantinib 4budigalimab 4Specimen Handling 4Sirolimus 4Interleukin-2 4Fluorouracil 4Doxorubicin 4Capecitabine 4130-nm albumin-bound paclitaxel 4spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Hepatocellular × brivanib × Clear all
NCT01540461 2014-07-08

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Bristol-Myers Squibb

Phase 1 Completed
17 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00437424 2011-05-04

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡